Core Viewpoint - The A-share market has seen a significant pullback in several brain-computer interface (BCI) concept stocks, with notable declines among various companies [1] Group 1: Stock Performance - Companies such as 麦澜德 (Mikland) and 熵基科技 (Entropy Technology) experienced declines exceeding 10% [1] - 诚益通 (Chengyi Tong) and 雷迪克 (Redik) fell over 7% [1] - 博拓生物 (Botuo Bio) and 爱朋医疗 (Aipeng Medical) dropped more than 6% [1] - 可孚医疗 (Kefu Medical) and 翔宇医疗 (Xiangyu Medical) decreased over 5% [1] - 狄耐克 (Dinaike) and 伟思医疗 (Weisi Medical) saw declines greater than 4% [1] Group 2: Company Announcements - Multiple BCI concept stocks issued announcements indicating a cooling off in the market [1] - 航天长峰 (Aerospace Changfeng) stated that the company has not actually engaged in BCI-related business [1] - 伟思医疗 (Weisi Medical) mentioned that new products in the BCI field are still in the early stages of market cultivation [1]

Group 1 - The A-share market has seen a significant pullback in brain-computer interface (BCI) concept stocks, with notable declines in companies such as Mailland and Entropy Technology, which fell over 10% [1] - Several BCI concept stocks have issued announcements indicating a cooling off, with Aerospace Changfeng stating that it has not actually engaged in BCI-related business [1] - Weisi Medical mentioned that its new products in the BCI field are still in the early stages of market cultivation [1] Group 2 - Specific stock performance includes Mailland down 10.68% with a market cap of 5.468 billion, Entropy Technology down 10.13% with a market cap of 10.1 billion, and Chengyi Tong down 7.55% with a market cap of 6.985 billion [2] - Other notable declines include Leedick down 7.14%, Botao Biological down 6.37%, and Aipeng Medical down 6.38% [2] - The overall trend shows that many BCI-related stocks are experiencing a downturn, with declines ranging from 4.33% to 10.68% across various companies [2]

Core Viewpoint - The brain-computer interface (BCI) concept continues to gain traction, with multiple listed companies responding positively to the trend, leading to significant stock price increases in the sector [1]. Company Responses - On January 6, several companies, including Weisi Medical, Sanbo Brain Science, Aipeng Medical, and others, saw their stocks hit the daily limit, with many achieving consecutive gains [3]. - Weisi Medical reported a 20.01% increase in stock price, indicating a strong market response to its developments in the neuro-rehabilitation field, expanding from single-device solutions to comprehensive "diagnosis-treatment-rehabilitation" offerings [4][5]. - Sanbo Brain Science highlighted the promising applications of BCI technology in clinical diagnosis and neuro-rehabilitation, also achieving a 20.01% stock price increase [7]. - Xiangyu Medical announced the establishment of a BCI laboratory and aims to develop a product system covering four major categories, also achieving a two-day stock increase [8]. - Aipeng Medical's stock rose by 20%, emphasizing the role of BCI as a bridge between the brain and external devices [9][10]. - Entropy Technology and Meihua Medical also reported significant stock increases, with the former focusing on BCI and vehicle-road collaboration technologies [11][12]. Industry Developments - Companies are actively engaging in the BCI sector, with Xiangyu Medical entering over 500 medical institutions and aiming for over a thousand top-tier hospitals nationwide, indicating a robust commercialization strategy [15]. - Mcland anticipates obtaining its first BCI medical device registration certificate by Q1 2026, which could accelerate the application of BCI technology in existing product lines [15]. - Chengdu Huayi and Yingjixin are focusing on the foundational hardware for BCI, with Chengdu Huayi developing high-precision ADCs and low-power FPGAs for signal processing [15][16]. - The integration of BCI with embodied intelligence is gaining attention, with companies exploring applications in smart healthcare and rehabilitation [17]. - Blue Si Technology announced its strategic investment in Qiang Brain Technology, which recently secured approximately 2 billion yuan in funding, marking it as the second-largest financing in the BCI field after Neuralink [18]. Market Outlook - The global BCI market is projected to reach approximately $12.4 billion by 2034, with a CAGR of 17% from 2025 to 2034, driven by technological advancements and increased capital investment [20]. - The transition of BCI from clinical validation to commercial scalability is expected to unlock significant market opportunities in healthcare and consumer sectors [20].

Group 1 - On January 6, a total of 22 stocks appeared on the Longhu list with the presence of Shenzhen Stock Connect special seats among the top five trading departments [1] - The net purchases included stocks such as Shanzi Gaoke, Zhongchao Holdings, and Qiangli New Materials, with net buying amounts of 150.91 million, 104.95 million, and 94.51 million respectively [1][2] - The net sales included stocks like Zhongtian Rocket, Haige Communication, and Tongyu Communication, with net selling amounts of 71.78 million, 54.57 million, and 53.40 million respectively [1][2] Group 2 - The stocks with the highest net purchases included: - Shanzi Gaoke (150.91 million) with a daily increase of 10.12% and a turnover rate of 12.69% [2] - Zhongchao Holdings (104.95 million) with a daily increase of 9.99% and a turnover rate of 34.29% [2] - Qiangli New Materials (94.51 million) with a daily increase of 15.84% and a turnover rate of 36.12% [2] - The stocks with the highest net sales included: - Zhongtian Rocket (-71.78 million) with a daily increase of 8.05% and a turnover rate of 15.76% [2] - Haige Communication (-54.57 million) with a daily increase of 9.98% and a turnover rate of 16.67% [2] - Tongyu Communication (-53.40 million) with a daily increase of 3.38% and a turnover rate of 40.79% [2]

Core Insights - The brain-computer interface (BCI) industry is transitioning from "scientific experiments" to "commercialization," with Neuralink planning large-scale production by 2026, igniting market expectations [1] - China is accelerating its progress in the BCI field through supportive policies and technological breakthroughs, with significant investments being made in the sector [1][12] - The market is characterized as a "0 to 1" incremental market, driven by short-term sentiment from Neuralink's production expectations and favorable domestic policies [1] Investment Landscape - Strong Brain Technology recently completed approximately 2 billion yuan in financing, marking the second-largest funding round in the BCI sector after Neuralink [1] - Investors are advised to focus on companies with core technological advantages, such as self-developed chips and flexible electrodes, as well as those that can achieve commercial closure in rehabilitation and consumer electronics [1] Technology Comparison - The BCI technology landscape is divided into invasive, semi-invasive, and non-invasive routes, each with distinct differences in signal quality, safety, and commercialization timelines [2] - Invasive methods, like those used by Neuralink, involve surgical implantation of electrodes for high-resolution signal acquisition but come with high costs and long development cycles [5] - Non-invasive methods utilize external sensors for signal collection, offering lower costs and safety but facing challenges with signal attenuation [8] Competitive Landscape - The U.S. leads in invasive BCI technology by 2-5 years, while China is catching up, particularly in non-invasive applications where both countries are on par [9][11] - Chinese companies are making significant strides in clinical trials, with several achieving notable milestones in both invasive and non-invasive technologies [12] Company Developments - Companies like BrainCo and Huashan Hospital have completed pioneering clinical trials in invasive BCI systems, demonstrating the ability to control devices through thought [12][13] - Strong Brain Technology has received FDA and CE certifications, positioning itself as a leader in the commercialization of BCI products [12] - Other companies, such as Beijing Chip Intelligence and ZhiDian Medical, are also advancing in the invasive BCI space, with various clinical trials and product developments underway [13][14] Regulatory Environment - The Chinese government has included BCI in its national strategic emerging industries, with plans for independent billing standards and industry regulations to facilitate commercialization [11]

证券代码：300430 证券简称：诚益通 公告编号：2026-001 北京诚益通控制技术集团股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 北京诚益通控制技术集团股份有限公司（以下简称 "公司"）（证券代码： 300430；证券简称：诚益通）股票于 2026 年 1 月 5 日、2026 年 1 月 6 日连续二 个交易日收盘价格涨幅偏离值累计达到 40.30%，根据《深圳证券交易所股票交 易规则》的有关规定，属于股票交易异常波动的情形。 二、公司关注并核实情况说明 三、是否存在应披露而未披露信息的说明 公司董事会确认，除在指定媒体已公开披露的信息外，公司目前没有任何根 据《深圳证券交易所创业板股票上市规则》等有关规定应予以披露而未披露的事 项；董事会也未获悉公司有根据《深圳证券交易所创业板股票上市规则》的有关 规定应予以披露而未披露的、对公司股票及其衍生品种交易价格产生较大影响的 信息；公司前期披露的信息不存在需要更正、补充之处。 4、公司、控股股东和实际控制人不存在关于本公司的应披露 ...

诚益通今日涨停，全天换手率34.79%，成交额24.05亿元，振幅12.94%。龙虎榜数据显示，机构净卖出 1586.71万元，深股通净买入1916.46万元，营业部席位合计净买入4910.61万元。 深交所公开信息显示，当日该股因日收盘价涨幅达20.00%上榜，机构专用席位净卖出1586.71万元，深 股通净买入1916.46万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交4.43亿元，其中，买入成交额为2.48亿 元，卖出成交额为1.95亿元，合计净买入5240.36万元。 具体来看，今日上榜的营业部中，共有3家机构专用席位现身，即买五、卖三、卖五，合计买入金额 4217.66万元，卖出金额5804.37万元，合计净卖出1586.71万元，深股通为第二大买入营业部及第二大卖 出营业部，买入金额为5496.82万元，卖出金额为3580.36万元，合计净买入1916.46万元。 资金流向方面，今日该股主力资金净流入1.89亿元，其中，特大单净流入3.03亿元，大单资金净流出 1.14亿元。近5日主力资金净流入4.45亿元。（数据宝） 诚益通1月6日交易公开信息 | 买/ 卖 | 会员营业部名称 ...

今日涨跌幅居前的概念板块 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 002195 | 岩山科 技 | 10.00 | 1.28 | 49272.01 | 80.37 | | 300430 | 诚益通 | 19.99 | 34.79 | 18886.96 | 7.85 | | 301293 | 三博脑 科 | 20.01 | 2.21 | 14128.55 | 46.71 | | 002173 | 创新医 疗 | 10.02 | 1.26 | 11284.03 | 82.52 | | 000516 | 国际医 学 | 9.96 | 2.16 | 9211.37 | 37.34 | | 603716 | 塞力医 疗 | 10.00 | 3.53 | 7079.50 | 38.34 | | 300753 | 爱朋医 | 20.00 | 17.90 | 7057.72 | 11.41 | | --- | --- | --- ...

证券之星消息，1月6日通用设备板块较上一交易日上涨0.87%，诚益通领涨。当日上证指数报收于 4083.67，上涨1.5%。深证成指报收于14022.55，上涨1.4%。通用设备板块个股涨跌见下表： 从资金流向上来看，当日通用设备板块主力资金净流出21.83亿元，游资资金净流出4789.59万元，散户资 金净流入22.31亿元。通用设备板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002342 | 巨力索具 | 3.15 Z | 13.66% | -1.21亿 | -5.23% | -1.95 Z | -8.43% | | 600783 | 鲁信创投 | 2.00亿 | 10.55% | -1.12 Z | -5.90% | -8812.56万 | -4.65% | | 300430 | 诚益通 | 1.79亿 | 7.44% | -1.66 Z | -6.91% | -1276.06万 ...

Market Overview - The A-share market continued to rise, with the Shanghai Composite Index achieving a 13-day winning streak, closing at 4083 points, up 1.5% [1] - The total market turnover reached 2.83 trillion yuan, an increase of 265 billion yuan from the previous trading day, with over 4100 stocks rising and nearly 150 stocks hitting the daily limit [1] Sector Performance - The brain-computer interface sector saw significant gains, with stocks like Sanbo Brain Science and Weisi Medical hitting the daily limit [2][4] - The titanium dioxide sector also experienced a collective price increase, with companies like Anning Shares and Vanadium Titanium Shares reaching the daily limit [2][6] - Brokerage stocks rose, with Huashan Securities and Hualin Securities hitting the daily limit [2][8] - Other sectors that performed well included industrial metals, silicon energy, electronic paper, and chemical raw materials [2] Brain-Computer Interface Sector - The brain-computer interface sector was particularly strong, with stocks like Beiyikang and Weisi Medical seeing gains of around 20% [5] - Elon Musk announced that Neuralink, his brain-computer interface company, plans to start large-scale production in 2026, which has positively impacted the sector [4] Titanium Dioxide Sector - The titanium dioxide industry recently issued a price increase notice to reverse previous low pricing and low profitability, indicating a potential recovery in industry profits [6] - Major domestic titanium dioxide companies are accelerating the layout of chloride process capacity, with Tianyuan Co. announcing a 1.48 billion yuan investment in a new project [6] Brokerage Sector - The brokerage sector is benefiting from high market activity, with the Shanghai Composite Index recording a 12-day winning streak and turnover exceeding 1 trillion yuan [8] - Analysts suggest that the improved policy environment and influx of funds will enhance the investment value of the brokerage sector, supporting growth in wealth management and self-operated business revenues [8] Industrial Metals Sector - The industrial metals sector is experiencing price increases driven by both financial and commodity attributes, with low global copper and aluminum inventories and expected demand growth from the recovering Chinese economy [12] - Stocks like Liyuan Shares and Chang Aluminum have seen significant gains, with some hitting the daily limit [13] Electronic Paper Sector - The electronic paper sector is also on the rise, with Su Dawei and other companies achieving substantial gains following a collaboration announcement with Shanghai Yudi Optoelectronics [14][15]